Professor of Medicine (Infectious Diseases) and of Microbial Pathogenesis; Affiliated Faculty, Yale Institute for Global Health
Department Chair and Professor of Epidemiology (Microbial Diseases); Professor of Pediatrics (Infectious Disease) and Microbial Pathogenesis; Interim Director, Yale Institute for Global Health; Associate Director, MD-PhD ProgramMichael Cappello MD is Professor and Chair of the Department of Epidemiology of Microbial Diseases at the Yale School of Public Health, and Professor of Pediatrics and Microbial Pathogenesis at Yale Medical School. He graduated from Brown University with a degree in Biomedical Ethics and received his MD from Georgetown University in Washington, DC. After training in adult and Pediatric infectious diseases at Yale, Dr. Cappello joined the faculty in 1995, where he oversees a laboratory and field based research program focused on global health, tropical medicine and molecular parasitology. He is a 2007 recipient of the Bailey K. Ashford medal, awarded by the American Society of Tropical Medicine and Hygiene “for distinguished work in tropical medicine.” In addition to research, Dr. Cappello provides clinical care as an Infectious Diseases specialist at Yale New Haven Children’s Hospital. He is co-founder of the Yale Partnerships for Global Health, an initiative that advances scientific knowledge, promotes international understanding, and builds human capacity through collaborative research and training. From 2007-15, Dr. Cappello directed the Yale World Fellows Program, a multi-disciplinary, campus-wide initiative whose mission is to cultivate and inspire a global network of leaders committed to positive change. From 2016-21, he chaired the Council on African Studies at the Whitney and Betty MacMillan Center for International and Area Studies and was faculty director of the Yale Africa Initiative. Dr. Cappello is a member of the Council on Foreign Relations and serves on the Academic Advisory Council of Schwarzman Scholars Program at Tsinghua University in Beijing.
Professor of Chemistry and of Microbial Pathogenesis
Associate Professor of Medicine (Pulmonary, Critical Care and Sleep Medicine) and of Microbial Pathogenesis; Director, Center for Pulmonary Infection Research and Treatment (CPIRT)Dr. Dela Cruz completed his research training through an MD/PhD program in the area of immunology and virology from University of Toronto and Yale. Clinically, he is trained in internal medicine, and specializes in pulmonary and critical care medicine and is currently an Associate Professor at Yale University in the same department. He is also the founding director for the Center for Pulmonary Infection Research and Treatment (CPIRT). www.cpirt.yale.edu. His laboratory is interested in studying the role of respiratory infection in the pathogenesis of acute and chronic lung diseases. Specifically, his work focuses on how lung infection contribute to inflammation, injury and tissue repair in the lung. This has allowed the lab to carefully study the molecular and cellular responses of several novel mediators in the lung.His laboratory focuses on two main research programs. (1) Studying novel immune regulators in the lung during respiratory infections. (2) Studying the effects of cigarette smoke (CS) exposure in the pathogenesis of airway and lung diseases such as chronic obstructive pulmonary disease (COPD) using preclinical genetic mouse models and human biosamples. The goal of the lab is also to be able to confirm and translate the findings using biospecimens from the established and establishing cohort of human patients with various lung diseases.COPD is a composite entity that includes chronic bronchitis and emphysema, is a leading cause of death in the world, and is a disease that is in need of new treatments. One of the goal of our laboratory is to investigate the interaction between CS and respiratory virus infection in the pathogenesis of COPD and identify novel therapeutic targets for this respiratory disease. It has been long thought that the frequent respiratory infections in COPD patients are due to their depressed immune function. Our studies have revealed that CS-exposed hosts have an over-exaggerated immune reaction to viral infections. Frequent acute COPD exacerbations correlate with increased rate of disease progression and more loss of lung function in COPD especially if it is due to viral infections. Our studies have shown that CS exposure has an impressive ability to regulate the innate immunity in the lung after influenza virus and respiratory syncytial virus (RSV) infection. CS enhances the inflammation, alveolar destruction and airway fibrosis caused by influenza virus and RSV. These effects are mediated by type I interferon and RIG-like helicase antiviral innate immune pathway. CS exposure also results in the induction of interleukin-15 in the setting of these respiratory infections. We hypothesize that these novel mechanistic pathways may explain the heightened inflammatory response and worsening lung functions in COPD patients with multiple virally-induced exacerbations, and the chronic lung inflammation seen in stable COPD patients. We have also translated our findings by studying these immune mediators in patients infected with various respiratory viruses and have thus far collected >300 human biosamples.YCCI Scholar 2011
Waldemar Von Zedtwitz Professor of Medicine (Infectious Diseases) and Professor of Epidemiology (Microbial Diseases) and of Microbial Pathogenesis; Affiliated Faculty, Yale Institute for Global Health; Section Chief, Infectious Diseases, Internal MedicineMy laboratory investigates vector-borne diseases. Studies are directed toward understanding Lyme disease, flaviviral infections including dengue and West Nile viruses, and malaria. Efforts on Lyme disease include exploring immunity to Borrelia burgdorferi, selective B. burgdorferi gene expression in vivo, and the immunobiology of Lyme arthritis. Flaviviruses and Plasmodium are used as models to understand the molecular interactions between pathogens, their arthropod vectors and their mammalian hosts. Finally, we are developing new approaches to prevent ticks and mosquitoes from feeding on a vertebrate host, thereby interfering with pathogen transmission.
Associate Professor of Medicine (Infectious Diseases) and of Microbial Pathogenesis; Director ID/Rheum Research Conference, Internal MedicineI received my M.D. and Ph.D. from the University of Chicago in the Medical Scientist Training Program (MSTP). My Ph.D. was from the Department of Molecular Genetics and Cell Biology on the pathogenesis of Herpes simplex virus; followed by medical residency and Infectious Diseases training was at Washington University in St. Louis where I was a Howard Hughes Research Fellow. I joined the Indiana University faculty in 2001 to work on Chlamydia pathogenesis, which remains my research focus to the present day.
Gustavus and Louise Pfeiffer Research Foundation M.D.-Ph.D. Program Director and Professor of Medicine (Infectious Diseases) and of Microbial Pathogenesis; Professor, Microbial Pathogenesis; Director, MD-PhD Program, Yale UniversityDr. Kazmierczak received her PhD from Rockefeller University (1993) and her MD from Cornell University Medical College (1994), both in New York City. She completed an Internal Medicine residency and Infectious Diseases fellowship training at the University of California, San Francisco, and joined the Yale faculty in 2001. She is currently a Professor of Medicine and Microbial Pathogenesis, and Director of the MD-PhD program at Yale. Dr. Kazmierczak's research program is broadly focused on bacterial and host factors that allow opportunistic infections to occur. Using Pseudomonas aeruginosa as a clinically relevant model, her lab addresses fundamental questions of how cell-envelope spanning bacterial machines - the Type 3 secretion system, Type 4 pili and polar flagellum - are assembled, regulated, and used during infection. She has also identified host responses directed at components of these virulence associated structures, in particular those mediated by the NLRC4 inflammasome. Inflammatory responses to bacteria are also a focus of her work on microbiome-host interactions in infants with Cystic Fibrosis, where her lab has used longitudinal data acquired over five years from cohorts of patients and controls to understand gut microbiome composition and the inflammatory and metabolic responses at this site. Dr. Kazmierczak has been recognized as a Burroughs-Wellcome Fund Investigator in the Pathogenesis of Infectious Diseases (2007), a Donaghue Investigator (2002), and a Hellman Family Fellow (2002). She is a Fellow of the Infectious Diseases Society of America and an elected member of the American Society for Clinical Investigation and the American Academy for Microbiology.
Associate Professor of Infectious Diseases and of Microbial Pathogenesis; Director of Graduate Admissions, The BBS Microbiology Track; Director, Yale Predoctoral Training Program in Virology, Virology Laboratories; Chartered Member, Study Section: NIH: NIAID- AIDS Discovery And Development Of Therapeutics, National Institutes of Allergy and Infectious DiseasesDr. Priti Kumar received her PhD in Immunology from Indian Institute of Science in the year 2002. After completing her postdoctoral studies from Harvard Medical School, she joined as an Assistant Professor at Yale University in the year 2008. Currently, she is Associate Professor of Infectious Diseases at Yale University School of Medicine. Her laboratory conducts translational research with a focus on treatment of diseases caused by RNA viruses. For the last 12 years as faculty at Yale, she made key contributions towards the development and testing of gene therapy and cure based approaches that overcome in vivo biological barriers to enable the use of next-generation biologicals like nucleic acids such as siRNA, nucleases such as recombinases and CRISPRs and antibodies with effector function for their therapeutic potential against viruses like HIV-1, West Nile virus, Japanese encephalitis virus, dengue and now, SARS-COV2. Her laboratory is well-recognized for studies on HIV-1 in state-of-the-art humanized mouse models that allow characterization of virus pathogenesis in the context of a human immune system. Her laboratory also conducts pioneering research on live-imaging pathogenesis of infectious viruses in small animal models.
Assistant ProfessorDr. Maudry Laurent-Rolle received her B.S. from Long Island University, Brooklyn Campus in Biology in 2001. She then obtained her MD and PhD from Icahn School of Medicine at Mount Sinai. Her dissertation research was funded by an NIH pre-doctoral fellowship, which allowed her to examine the molecular mechanisms by which flaviviruses inhibit host innate immune responses. She completed residency training in Internal Medicine at Albert Einstein/Montefiore Medical Center in 2016 then joined the Infectious Diseases Fellowship program here at Yale University. Her research focus is on vaccine design and development of antivirals. She is originally from the beautiful Caribbean island of Dominica, known for its many rivers, tropical rainforests, and natural hot springs.
Professor of Medicine (Infectious Diseases) and of Microbial Pathogenesis; Chief, Infectious Diseases at VACTAfter finishing his undergraduate studies at Brown University, Dr. Sutton enrolled in the MSTP at Stanford, where he obtained his PhD degree with Dr. John Boothroyd, working on trans-splicing in African trypanosomes. He then completed a categorical residency in internal medicine at the Hospital of the University of Pennsylvania and a fellowship in infectious diseases at UCSF. After post-doctoral stints with Drs. Harold Varmus, Dan Littman, and Pat Brown in which he worked on HTLV cell binding and entry and the development of HIV-based gene therapy vectors, he joined the faculty at Baylor College of Medicine. In 2008 he was recruited to Yale to continue his work on HIV replication and lentiviral vectors. Dr. Sutton spends approximately 50% of his time at the research bench and 25% in the clinical setting, both out-patient and in-patient, mainly at the West Haven VA (VACT). He is also the chief of Infectious Diseases at VACT, which takes up 25% of his time. Dr. Sutton took an administrative leave of absence in mid-April 2022, but he resumed all of his clinical, educational, and research activities before the beginning of 2023.